ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Metformin Weight Loss Combo: Effect of Leucine plus Metformin and Sildenafil Combination
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 132108" data-attributes="member: 13851"><p><strong>Objective:</strong> Leucine was previously demonstrated to allosterically activate mammalian sirtuin 1 and synergize with other sirtuin 1/AMP-activated protein kinase/nitric oxide pathway activators to modulate energy metabolism. The objective of this study was to evaluate the effects of a triple combination of leucine, metformin, and sildenafil (NS-0200) on body weight and obesity comorbidities in a phase 2 randomized trial.</p><p></p><p><strong>Methods: </strong>A total of 91 subjects with obesity were randomized to placebo, low dose (1.1 g leucine/0.5 g metformin/0.5 mg sildenafil), or high dose (1.1 g leucine/0.5 g metformin/1.0 mg sildenafil) twice daily for 16 weeks. Seventy subjects completed the trial and met all a priori compliance criteria. Hypertensive (n=35) and hypertriglyceridemic (n=22) sub cohorts were also analyzed.</p><p></p><p><strong>Results:</strong> NS-0200 dose-responsively reduced weight; high dose reduced weight by 2.4 and 5.0 kg in the full and high-triglyceride cohorts, respectively (P<0.0001). High-dose NS-0200 treatment also decreased blood pressure (−5.5 mm Hg diastolic pressure; P=0.011), with greater effects among hypertensive subjects. NS-0200 also significantly reduced triglycerides and hemoglobin A1c. Significant improvement in ≥ 2 comorbidities was exhibited by 54% of subjects in the high-dose arm versus 5% of placebo subjects (P=0.0009). Treatment-emergent adverse events did not significantly differ among groups.</p><p></p><p><strong>Conclusions:</strong> These data support further study of NS-0200 as a therapy for obesity and associated comorbidities.</p><p></p><p>Overall, <span style="color: rgb(184, 49, 47)"><strong>data from the present study demonstrate that treatment with NS-0200 resulted in significant, dose-dependent reductions in body weight and concomitant improvements in multiple obesity comorbidities</strong></span>. These data support further development of NS-0200 as a therapy for obesity that exerts potential independent effects on obesity-associated comorbidities.</p></blockquote><p></p>
[QUOTE="madman, post: 132108, member: 13851"] [B]Objective:[/B] Leucine was previously demonstrated to allosterically activate mammalian sirtuin 1 and synergize with other sirtuin 1/AMP-activated protein kinase/nitric oxide pathway activators to modulate energy metabolism. The objective of this study was to evaluate the effects of a triple combination of leucine, metformin, and sildenafil (NS-0200) on body weight and obesity comorbidities in a phase 2 randomized trial. [B]Methods: [/B]A total of 91 subjects with obesity were randomized to placebo, low dose (1.1 g leucine/0.5 g metformin/0.5 mg sildenafil), or high dose (1.1 g leucine/0.5 g metformin/1.0 mg sildenafil) twice daily for 16 weeks. Seventy subjects completed the trial and met all a priori compliance criteria. Hypertensive (n=35) and hypertriglyceridemic (n=22) sub cohorts were also analyzed. [B]Results:[/B] NS-0200 dose-responsively reduced weight; high dose reduced weight by 2.4 and 5.0 kg in the full and high-triglyceride cohorts, respectively (P<0.0001). High-dose NS-0200 treatment also decreased blood pressure (−5.5 mm Hg diastolic pressure; P=0.011), with greater effects among hypertensive subjects. NS-0200 also significantly reduced triglycerides and hemoglobin A1c. Significant improvement in ≥ 2 comorbidities was exhibited by 54% of subjects in the high-dose arm versus 5% of placebo subjects (P=0.0009). Treatment-emergent adverse events did not significantly differ among groups. [B]Conclusions:[/B] These data support further study of NS-0200 as a therapy for obesity and associated comorbidities. Overall, [COLOR=rgb(184, 49, 47)][B]data from the present study demonstrate that treatment with NS-0200 resulted in significant, dose-dependent reductions in body weight and concomitant improvements in multiple obesity comorbidities[/B][/COLOR]. These data support further development of NS-0200 as a therapy for obesity that exerts potential independent effects on obesity-associated comorbidities. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Metformin Weight Loss Combo: Effect of Leucine plus Metformin and Sildenafil Combination
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top